Evidence map›Paper›PMID 23303812›Full record

ArticleThe Journal of infectious diseases2013

GB virus type C E2 protein inhibits human immunodeficiency virus type 1 assembly through interference with HIV-1 gag plasma membrane targeting.

Christine L Timmons, Qiujia Shao, Chenliang Wang, Ling Liu, Huanliang Liu, Xinhong Dong, Bindong Liu

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Experimental and therapeutic medicine · 2018
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Christine L TimmonsCenter for AIDS Health Disparities Research, Meharry Medical College, Nashville, TN 37208, USA.
Qiujia Shao
Chenliang Wang
Ling Liu
Huanliang Liu
Xinhong Dong
Bindong Liu
Meharry Medical College · USSun Yat-sen University · CN

Funding

VITAMIN D DEFICIENCY AND INCREASED RISK OF UTERINE FIBROIDS IN AFRICAN AMERICANSG12RR003032 · NCRR · MEHARRY MEDICAL COLLEGE · PI LIU, BINDONG · 1985 to 2011
$27.4M
Technologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7M
THE MEHARRY RISE INITIATIVER25GM059994 · NIGMS · MEHARRY MEDICAL COLLEGE · PI MOTLEY-JOHNSON, EVANGELINE D · 1999 to 2021
$23.0M
Translational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI BALLARD, BILLY RAY · 2011 to 2025
$18.8M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54RR026140 · NCRR · MEHARRY MEDICAL COLLEGE · PI GOODWIN, JEFFREY SHAWN · 2009 to 2011
$12.9M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
WALDEMAR POPIK, PHD, LAB STARTUP PACKAGE: HIVU54RR019192 · NCRR · MEHARRY MEDICAL COLLEGE · PI ALCENDOR, DONALD JAMES · 2003 to 2009
$10.3M
Meharry RCMI Program in Women's Health ResearchG12MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI HILDRETH, JAMES E · 2012 to 2016
$7.8M
Research Training in Cardivascular Biology at MeharryT32HL007737 · NHLBI · MEHARRY MEDICAL COLLEGE · PI MARTIN, PAMELA M · 1993 to 2025
$4.7M
MOLECULAR PARASITOLOGY TRAINING PROGRAMT32AI007281 · NIAID · MEHARRY MEDICAL COLLEGE · PI NDE, PIUS N · 1985 to 2025
$3.2M
Characterizing a small molecule of Streptococcus cristatus for HIV drug designSC1GM089269 · NIGMS · MEHARRY MEDICAL COLLEGE · PI LIU, BINDONG · 2009 to 2019
$2.6M
NCI NIH HHS U54 CA163069NCRR NIH HHS G12 RR003032NCRR NIH HHS U54 RR019192NCRR NIH HHS U54 RR026140NCRR NIH HHS U54RR026140NHLBI NIH HHS 5T32HL007737NHLBI NIH HHS T32 HL007737NIAID NIH HHS 5T32AI007281NIAID NIH HHS P30 AI054999NIAID NIH HHS P30AI054999NIAID NIH HHS T32 AI007281NIGMS NIH HHS 2R25GM059994NIGMS NIH HHS R25 GM059994NIGMS NIH HHS SC1 GM089269NIGMS NIH HHS SC1GM089269NIMHD NIH HHS G12 MD007586NIMHD NIH HHS G12MD007586NIMHD NIH HHS U54 MD007593NIMHD NIH HHS U54MD007593
6 · The paper itself

Abstract

GB virus type C (GBV-C) is a single-stranded positive-sense RNA virus classified in the Flaviviridae family. Persistent coinfection with GBV-C is associated with lower human immunodeficiency virus type 1 (HIV-1) load, higher CD4(+) T-cell count, and prolonged survival in HIV-1 coinfected patients. The GBV-C envelope glycoprotein E2 has been reported to interfere with HIV-1 entry. In this study, we showed that the expression of GBV-C E2 inhibited HIV-1 Gag assembly and release. Expression of glycosylated GBV-C E2 inhibited HIV-1 Gag precursor processing, resulting in lower production of CAp24 and MAp17, while the overall expression level of the Gag precursor Pr55 remained unchanged. Membrane floatation gradient and indirect immunofluorescence confocal microscopy analysis showed that glycosylated E2 disrupted HIV-1 Gag trafficking to the plasma membrane, resulting in Gag accumulation in subcellular compartments. This interference in HIV-1 Gag trafficking led to diminished HIV-1 particle production, which is a critical step for HIV-1 to infect new host cells. These findings shed light on a novel mechanism used by GBV-C E2 to inhibit HIV-1 replication and may provide insight into new approaches for suppressing HIV-1 replication.

Indexed as

Virus AssemblyCD4 Lymphocyte CountCell MembraneCoinfectiongag Gene Products, Human Immunodeficiency VirusGB virus CGlycosylationHEK293 CellsHeLa CellsHIV-1HIV InfectionsHumansPlasmidsProtein Structure, TertiaryProtein TransportTransfectiongag Gene Products, Human Immunodeficiency Virusglycoprotein E2, GB virus CViral Envelope Proteins

Identifiers

PMID23303812
PMCPMC3583272
OpenAlexW2110027366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.